According to statement by BIO President and CEO Jim Greenwood, billionaire hedge fund manager Kyle Bass continues to attack biotechnology companies with endless Inter Parte Review challenges to legitimate patents. Four new IPR filings against Acorda Therapeutics are particularly egregious, coming on the heels of Bass’ prior failed attempt to attack 2 of those same patents covering multiple sclerosis drug Ampyra. BIO again calls on PTO and Congress to quickly take action to stop this abuse.